Board Member
Enanta Pharmaceuticals Inc (ENTA)Equibles does not estimate personal net worth.
Get an email with a short summary when Enanta Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get ENTA alertsJay R. Luly is recorded as Board Member at Enanta Pharmaceuticals Inc (ENTA) since January 1, 2003. The newest filing on record that lists Jay R. Luly as Board Member at Enanta Pharmaceuticals Inc (ENTA) is dated January 26, 2026. Enanta Pharmaceuticals Inc reported in an 8-K filed October 28, 2026 that Jay R. Luly retired as President and Chief Executive Officer, effective February 1, 2027. The proxy statement of Enanta Pharmaceuticals Inc reports total compensation of $2,769,548 for Jay R. Luly in fiscal 2025, including a base salary of $803,300. Disclosed compensation is on record for 9 fiscal years. Jay R. Luly has spoken on 1 investor event across 1 company, most recently for Enanta Pharmaceuticals Inc on June 4, 2026. Enanta Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Enanta Pharmaceuticals Inc includes Harry R. Trout, III (CFO), Paul Mellett (CFO), Tara L. Kieffer, Ph.D. (COO) and 4 others.
“WATERTOWN, Mass., October 28, 2026 – Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces today that Jay R. Luly, Ph.D., age 70, will retire as President and Chief Executive Officer, by February 1, 2027 following 23 years of leadership with the Company.”
“Before I begin, I want to remind you that I'll be making some forward-looking statements, and for a summary of the risks associated with these statements, please see our filings on sec.gov and on our website.”
2003-01-01–present
Last confirmed January 26, 2026
Start not stated–2027-02-01
Biotechnology · Healthcare
Board Member
2003-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Enanta Pharmaceuticals Inc (ENTA) | President and Chief Executive Officer | $803,300 | $2,769,548 |
| 2024 | Enanta Pharmaceuticals Inc (ENTA) | President and Chief Executive Officer | $779,875 | $2,695,276 |
| 2023 | Enanta Pharmaceuticals Inc (ENTA) | President and Chief Executive Officer | $755,375 | $7,856,698 |
| 2022 | Enanta Pharmaceuticals Inc (ENTA) | President and Chief Executive Officer | $725,050 | $7,272,656 |
| 2021 | Enanta Pharmaceuticals Inc (ENTA) | President and Chief Executive Officer | $693,188 | $5,293,709 |
| 2020 | Enanta Pharmaceuticals Inc (ENTA) | President and Chief Executive Officer | $667,063 | $5,197,837 |
| 2019 | Enanta Pharmaceuticals Inc (ENTA) | President and Chief Executive Officer | $641,825 | $4,483,503 |
| 2018 | Enanta Pharmaceuticals Inc (ENTA) | President and Chief Executive Officer | $611,178 | $4,464,199 |
| 2017 | Enanta Pharmaceuticals Inc (ENTA) | President and Chief Executive Officer | $581,203 | $4,281,102 |
